Good morning, everyone, and welcome to the Orthofix Second Quarter 2020 Earnings Results Conference Call. We will have a question-and-answer session later, and I will provide instructions then. I would now like to hand the conference over to your host, Alexa Huerta, Senior Director of Investor Relations and Finance. Please proceed.

Thank you, operator and good morning, everyone. Welcome to the Orthofix second quarter 2020 earnings call. Joining me on the call today are our President and Chief Executive Officer, Jon Serbousek; and Chief Financial Officer, Doug Rice. I’ll start with our safe harbor statements and then pass it over to Jon. During this call, we’ll be making forward-looking statements that involve risks and uncertainties. All statements other than those of historical facts are forward-looking statements, including any earnings guidance that we provide and any statements about our plans, beliefs, strategies, expectations, goals or objectives. Investors are cautioned not to place undue reliance on such forward-looking statements as there is no assurance that the matters contained in such statements will occur. The forward-looking statements we will make on today’s call are based on our beliefs and expectations as of today, August 6, 2020. We do not undertake any obligation to revise or update such forward-looking statements. Some factors that could cause actual results to be materially different from the forward-looking statements made by us on the call include the risks disclosed under the heading Risk Factors in our Form 10-K for the year ended December 31, 2019, and our Form 10-Q, expected to be filed later today, as well as additional SEC filings we make in the future. If you need copies of these documents, please contact our office at Orthofix in Louisville, Texas. In addition, on today’s call, we will refer to various non-GAAP financial measures. We believe that in order to properly understand our short-term and long-term financial trends, investors may wish to review these matters as a supplement to financial measures determined in accordance with US GAAP. Please refer to today’s press release announcing our second quarter 2020 results for reconciliations of these non-GAAP financial measures to our US GAAP financial results. At this point, I’ll turn the call over to Jon.

Thank you, Alexa. Welcome, everyone and thank you for joining us for our second quarter 2020 results conference call. Before getting into my prepared remarks, I’d like to introduce you to Alexa Huerta, who will be taking over as our Head of Investor Relations. Alexa has been with our finance group for over eight years, and we are excited to now have her in this role. Mark Quick, who most of you have interacted with over the past, has taken a leadership role in our business development group. Mark will be transitioning IR responsibilities to Alexa over the coming quarters. On today’s call, I’ll start by discussing the impact of COVID-19 as it had on our business, after which I’ll provide an update on our second quarter performance. I will then review the progress we’ve made in each of our strategic initiatives before handing the call over to Doug, who will provide financial updates. I will close with our perspective on the business going forward, including an update on the trends we are seeing through July, before opening the line for questions. Starting with the COVID-19 update. I’d like to start by saying on behalf of everyone at Orthofix how thankful we are for the tireless work being done by everyone in the global healthcare community to address this crisis. I’d also like to thank each and every one of our employees who have executed incredibly well during these challenging times. The magnitude of this pandemic and the challenges presented for patient care created an unprecedented environment, and I’m truly proud of the resolve and adaptability of our team. With that in mind, we continue to actively monitor the situation with a focus on safely and effectively supplying our customers while taking care of their patient needs. On our last call in May, we provided you with an update on all the actions we took to keep our employees and their families safe and ensure we maintain business continuity. During the second quarter, we focused on making sure our facilities and operations were adapted to this new COVID environment and implemented new office procedures to ensure everyone feels safe in the office. As I will discuss during my later comments, I’m very proud of our proactive measures and accomplishments during this difficult time as represented by our ability to adapt operationally and execute on our strategic plan; effectively integrate FITBONE into our commercial channel. Our strategic progress toward creating a high velocity new product innovation program. The increase of safety stock for key products as a hedge against the potential supply chain disruption and successful management of cash as demonstrated by our election to repay $50 million of the $100 million advance we took in the second quarter. Now shifting to second quarter performance. Total revenue in the quarter was down 37% on a reported and constant currency basis compared to the prior year quarter. The year-over-year decrease was largely driven by a significant decline in elective procedure volumes during the quarter, which represented the majority of our procedures. To provide more insight into our performance during the second quarter, I will provide you with our monthly sales during the second quarter. Total revenue compared to the three months of the second quarter of 2019 was as follows: April was the weakest month of the quarter down approximately 60% versus the prior year month; May showed recovery and was down approximately 40% versus the prior year month; and June was the strongest month of the quarter down approximately 15% versus the prior year month. Overall, we are very encouraged by the performance that we saw during the second quarter, which has continued into July, where net sales were down less than 10% compared to the prior year month. This reflects strong execution and nimble management in the face of our uncertainty. We believe the drivers of this recovery were patients, surgeons, and hospitals as they address the surgical backlog in regions that reopened for elective procedures and the execution of our sales leadership team. We are very optimistic about the long-term opportunities in the business segments in which we operate, but remain cautious about the balance of the year. We believe it is too early to predict a return to normalcy in the near term and the unpredictable nature of our current environment, including comfort levels of patients to return to the clinics, continuing localized shutdowns, increased unemployment leading to a lack of medical coverage, and hospital capacity constraints. Now let’s turn to the performance within each of our business units. Starting with Bone Growth Therapies. Sales were down 43% versus the prior year. Bone Growth Therapies was greatly impacted by COVID in the quarter, particularly in procedure volumes during April and May. We saw a rebound in June as order volumes picked up nicely compared to the prior two months. Moving to Spinal Implants. Sales were down 20% constant currency versus the prior year. This category is made up of our spine fixation and motion preservation products, which are, by and large, used in elective procedures. US Motion preservation sales were $3.6 million in the quarter, up significantly over the prior year and also sequentially up over the first quarter. We continue to see strong M6-C adoption trends, with June being our best month we’ve had to date in US sales. Our sales training team was able to virtually train over 75 US surgeons on M6-C during the second quarter of 2020, a subset of which performed cases that drove approximately $1 million of revenue in the quarter. In Biologics, sales were down 34% versus prior year, primarily as a result of reduction in elective procedure volumes. After a slower start in April, our procedure volumes are now right in line with our Spinal Fixation volumes. Moving on to the Extremities business. Sales were down 40% on a reported basis versus the prior year, primarily as a result of the impact of COVID on procedure volumes. While certain procedures in the Extremity business are non-elective, especially the trauma procedures, a large portion is comprised of deformity correction procedures, which are elective and can be postponed. Due to this mix of procedures, we believe the segment generally follows elective procedure trends. I would like to now provide you with a brief overview of the progress we have made within each of our strategic focus areas. Starting with our first initiative, structure and leadership. During the second quarter, we completed the integration of the Biologics and Spinal Implants product categories under a single sales management team. We are excited about this reorganization. By bringing these businesses under one sales management, we believe we can better leverage the portfolio and our brand, making it easier to do business with us as a company. Additionally, by establishing a unified sales structure we can support our commercial team with market-by-market strategy and decision-making. With this new structure in place and with the complete hiring of all key senior leadership roles in our Global Spine business, we are very optimistic about the future of Global Spine. Continuing with our leadership focus, we are pleased with our progress for the search of a new president of Global Extremities. We’ve identified several qualified candidates and are in the process of moving toward a selection. I look forward to making this announcement in the near term. Moving to our second initiative, operational execution. We have addressed the challenges associated with COVID. We continue to constantly deliver for our customers, which is a testament to our team. We are proud to say that there are no supply or manufacturing disruptions during the quarter. This was due in part to the rapid implementation of continuity initiatives put in place at the onset of the pandemic, as well as supply chain improvement initiatives implemented during the second quarter. We strategically realigned facilities to focus on near-term demand while at the same time, replenishing inventories to allow us to meet future product demand. While the majority of our focus has been on the short-term initiatives, our mid and long-term programs are receiving focus as well. Our third initiative is product innovation and differentiation. We made solid progress during the quarter delivering new products to the marketplace. I would like to first highlight the Firebird SI Fusion System. In June, we announced FDA clearance in the first patient implant for the Firebird SI Fusion System designed to compress and stabilize the sacroiliac or SI joint during fusion. The Firebird SI Fusion System is a 3D printed bone screw with nano service technology and currently launching in the US for treatment of SI joint dysfunction. The new system is another example of our commitment to providing innovative solutions and options that complement our growing product and procedure solutions portfolio. This is just one of our upcoming product launches slated for this year’s NASS conference in early October. While our virtual conference and setting will be a unique opportunity, we intend to use this event to launch a number of new products across the spine portfolio. Our new product innovation process and team are still developing, but as you can see, we are starting to gain traction as our entire spine team is focused on building our portfolio with innovative products and procedures. We plan to use the NASS conference to further showcase this progress. Moving on, we continue to make good early progress with FITBONE. While we are still in the process of integrating the acquisition, building inventories, and gaining additional regulatory clearance in the U.S., we have quickly delivered results by adding new surgeon users and bringing on new distribution partners. As we think about building out high volume surgical solution portfolios, one area of focus is the development of a market-leading limb reconstruction and deformity correction offering. It’s not every deformity is a candidate for external fixation. We are focused on offering both internal and external correction solutions. We made early progress toward this with FITBONE and now we’re adding JuniOrtho Plating Systems, which received FDA clearance and CE marking just recently. This innovative internal fixation system is designed to address the demands of advanced deformity and trauma reconstruction of the lower extremities, specifically for pediatric patients. The JuniOrtho Plating System is complemented by a preoperative planning software that assists in implant selection prior to the surgical procedure. This unique platform enables the surgeon to actually plan the osteotomy position to visualize the implant in relation to the anatomy. This aids in the selection of the size of the device to ensure the best fit and optimal positioning for the patient’s body. The JuniOrtho software is currently available in Europe and the U.S. release is planned for later this year. The JuniOrtho Plating System represents our continued commitment to advancing pediatric orthopedics by providing surgeons with the devices they need to treat even the smallest patients. A targeted launch will begin in the U.S. during the third quarter of 2020. Our fourth and final initiative is our commercial channel development. We continue to focus on adding and developing long-term strategic partners. During the quarter, we continued to expand training and product knowledge with over 1,000 surgeon representative training sessions. There were over 90 events during the second quarter of 2020 to facilitate sales training. In order to continue to support our physicians and distributor partners, we have started using remote case preparation in some instances without a change in service level. As I mentioned earlier, there were over 75 new M6 physicians trained in the quarter. We will continue to enhance and utilize our virtual training platform into the future. So in summary, we are very proud of our second quarter performance, which highlights the team’s efforts and initiatives throughout our organization, as well as the growing demand for our evolving portfolio of products in the marketplace. While COVID-19 creates a level of uncertainty in looking forward, we have worked to solidify our foundation, expand our talent, execute on our strategic initiatives, build a winning culture, and position Orthofix for long-term success. With that, I’ll now hand over the call to Doug for further commentary on our financial performance.

Thanks, Jon. I will provide additional details into our net sales and earnings results and then discuss some of our other financial measures. Many of the financial measures covered in today’s call are on a non-GAAP basis. Please also refer to today’s earnings release for further information regarding our non-GAAP reconciliations and disclosures. As Jon noted, total net sales for the quarter were $73.1 million, down 37% on a reported basis and constant currency basis when compared to the second quarter of 2019. Gross margin in the second quarter 2020 was 68% compared to 78% in the prior year period. The primary driver of this decrease was lower fixed cost absorption as well as the recognition of non-cash inventory reserves, both due to lower revenue from the COVID impact. As procedure volumes rebound and revenue increases, we expect gross margins to approach historical levels. Sales and marketing expenses were 59% of net sales in the second quarter 2020, up from 49% in the second quarter of 2019. This increase was primarily a result of the loss of leverage from lower revenue in the quarter and commission support for our direct sales reps. As we noted last quarter, this deleverage was partially offset by our near-term expense savings initiatives. G&A expenses were 21% of net sales in the second quarter of 2020, up from 19% in the prior year period. This increase as a percentage of net sales was due to deleverage from lower revenue in the quarter. This was offset by a step down in strategic initiative spending and lower succession and transition related expenses in the quarter, as well as our short-term expense savings actions, which included salary reductions, travel restrictions and a significant slowdown in hiring. On a sequential dollar basis, G&A decreased by $2.8 million or approximately 16% as a direct result of our short-term savings initiatives. We expect to keep some of these initiatives in place until we approach normal levels of net sales. R&D expenses for the second quarter were 12% of net sales, up from 8% in the prior year period. Since, on a dollar basis, our R&D expenses were approximately flat year-over-year, this percentage increase is primarily due to lower revenue in the quarter. We had increased spending related to the FITBONE acquisition and integration as well as additional spending on improvements in our quality systems and regulatory functions. This was offset by lower clinical study expenses due to patients postponing in-office follow-up appointments. Interest expense and other income for the quarter was $4.2 million, up from $200,000 in the second quarter of 2019. Although we did incur $500,000 in interest expense during the quarter from our bank borrowings, this was more than offset by $4.7 million of income from the Department of Health and Human Services as part of the CARES Act benefits. Adjusted EBITDA decreased to negative $5.6 million or negative 8% of revenue, down from $17.3 million or 15% of revenue in the second quarter of 2019. A significant portion of this deleverage was due to the lower sales from the impact of COVID and the remainder due to planned investments, partially offset by the short-term expense savings actions mentioned earlier. I would like to point out that we recognized the $2.1 million non-cash expense in the quarter related to the increased fair value of a liability related to the two remaining Spinal Kinetics milestone payments. Although this calculation was performed at the end of June, we expect that the fair value of this liability will continue to increase as we get closer to the expected milestone payment dates predicated on elective procedure volumes staying at or above current levels. Now turning to tax. We had GAAP income tax expense for the quarter of a negative 9% of income before taxes or $1.5 million as compared to GAAP income tax expense of 181% of income before taxes in the same period of 2019. The primary factors affecting our effective tax rate for the second quarter of 2020 were the financial expenses not recognized for tax purposes related to acquisition-related remeasurement, as well as refinement of our estimate related to possible loss carrybacks under the CARES Act. For our non-GAAP results, we will continue to use 27% as our adjusted effective long-term tax rate, which normalizes for acquisition-related expenses and certain law changes. For the second quarter 2020, we reported a GAAP loss of $0.96 per diluted share as compared to a loss of $0.03 per share in the second quarter 2019. After adjusting for certain items and when normalizing for tax using a non-GAAP long-term effective tax rate, adjusted EPS for the second quarter 2020 was a loss of $0.59 compared to earnings of $0.28 in the second quarter of 2019. As with adjusted EBITDA, a significant portion of this decline over the prior year for the second quarter was due to the lower sales from the impact of COVID and the remainder due to the planned investments related to our strategic focus areas, offset by the short-term expense savings we have mentioned. Moving onto the balance sheet highlights. Day sales outstanding or DSOs were 84 days at the end of the second quarter 2020, up from 63 days at the end of the second quarter 2019. This increase was primarily due to lower revenue in the period. The accounts receivable balance in the quarter went down $10.4 million sequentially from Q1 2020 and gives us comfort that we were able to continue to collect from our customers. Our inventory turns at the end of the second quarter 2020 were at 1.2 times, compared with 1.3 times in the second quarter of 2019. Regarding cash, cash equivalents and restricted cash we maintained a strong liquidity position, with $173 million at the end of the second quarter 2020, compared to $52 million at the end of the previous year’s second quarter. Note that this cash balance includes the second quarter $13.9 million advance payment from Medicare as part of the CARES Act. This advance will be recouped by Medicare in Q3 and Q4 2020 as we submit new Medicare claims for reimbursement. Also, as Jon mentioned earlier, in July, we repaid $50 million of the $100 million bank borrowings that we took as a precaution in April. Cash flow from operations for the second quarter 2020 was $17.6 million, up from $9.4 million in the second quarter 2019. While we were positive in the quarter, we did receive $18.5 million in relief as part of the CARES Act during the second quarter 2020. As the Medicare advance payment is settled throughout the third and fourth quarters, it will reduce our cash flow from operations. Our working capital in the second quarter was also bolstered by lower commission payments as well as collections outpacing billings. Capital expenditures were down in the quarter to $4.4 million from $5.4 million in the prior year period due to reduced spending on the remodel of our facilities, and a reduction from our near-term cash savings initiatives previously mentioned. Free cash flow which we define as cash flow from operations minus capital expenditures was an inflow of $13.2 million during the quarter. This was up from an inflow of $4 million in the second quarter last year. Lastly, I’d like to thank all of the employees and sales partners of Orthofix for executing everything from getting patients products on time, every time to making sure our facilities are safe at all times. This pandemic has had a deep impact but our team delivered impressive results during the quarter. I’m very grateful to work with such a dedicated team of people. I’ll now turn the call back over to Jon.

Thanks, Doug. Before discussing our outlook on the remainder of the year, I want to comment on the upcoming FDA Orthopedic and Rehabilitation Device Panel advisory committee meeting, which has been rescheduled for September 8, 2020. Our position on this has not changed and we believe, along with the other manufacturers of BGS devices, that maintaining Class III status is in the best interest of patients, prescribing physicians and payers and insurers that continued safety and efficacy of the device therapy. We believe our best-in-class Bone Growth Therapy products will continue to remain a Class III device. Should this get downgraded to a Class II with special conditions, we believe based on our experience that peers and surgeons would require any new entrant to the marketplace to provide robust safety and efficacy clinical data, proven technology and device efficacy, a clear reimbursement plan, and exceptional service and support. As we shift our outlook to the remainder of 2020, the scope and duration of the COVID-19 pandemic and the timing of the global recovery remains uncertain and as a result, we will not be providing forward-looking guidance at this time. Despite the uncertainty of the situation, we continue to believe that the second quarter will be our worst quarter of the year. We are seeing positive trends in the July business, as we noted, which points to a recovery in elective procedures. While we are optimistic about the pace and general timing of the recovery, we are aware that it is too early to confidently predict our business in the near term. However, the global recovery plays out, we are operationally and commercially ready to meet the needs of our hospitals and surgeon customers and we will continue to monitor the situation closely. During the COVID-19 disruption, we have maximized strategic and structural improvements and have continued to execute operationally to set up our organization to emerge more successfully and ready for the future. Our long-term view on the underlying dynamics of the Spine and Extremity markets remains bullish and unchanged as a result of the pandemic. While there will be volatility and uncertainty in the near term, patients will continue to require surgical intervention to improve their lives, and we will be there to help surgeons meet those patient needs. Thanks to everyone at Orthofix and all the healthcare providers around the world working to solve this challenge. With that, I would now like to open the line for questions.

Your first question comes from Raj Denhoy with Jefferies.

Hi. This is Zach on for Raj. Just a few for us. You mentioned sequential recovery on a procedural basis through July. How much of this recovery is into the backlog? And then how much is newly scheduled procedures?

Yeah. Thanks for the question. That is a difficult one to answer at this point in time. Clearly, there is a backlog, but we saw business continuity through those periods of time, and we did clear a good backlog during the period of time. We don’t know if there is an exact percentage of that left right out in the marketplace. But we will tell you over the next months, what’s left there, but we’re on the continuity now of procedures more so than backlog we believe.

Okay, helpful. And then, how have your sales reps been interacting with surgeons through the COVID pandemic and how do you think that interaction works moving forward as we get to some semblance of normalcy here?

Yeah. As we mentioned in the prepared remarks, we flipped very quickly to virtual interactions, not only in training, official training but also in how we ran sales calls and such. The good news is that surgeons, when they’re not operating or not seeing patients, they have time to talk to you, and so we took significant advantage of that. We will continue to use those measures going forward, but nothing replaces the interaction of face to face as far as detailing the attributes of the positive nature of your products and also building those relationships. But we’ll get back to the traditional methods in many locations. But we’ll continue to be used virtual technologies as well.

Okay. Great. And then one last one just on margins. Gross margin, as you mentioned, came in a bit light, and you said that it should recover to historical levels. Do you have any more detail on the timeline of that recovery? If it’s fluid, but just curious if you can provide more detail there.

It’s hard to say when the recovery will happen. It’s a fair question, but as we approach those historical rates, our COGS and margins should return to our historical levels. We hope sooner obviously like everybody else. And just as a reminder, until that happens, on our last call, we did guide or at least provide some insight into what our fixed variable mix was on some of the line items like COGS and sales and marketing. So happy to help in that way as well.

Perfect. Thank you.

Thank you.

And your next question comes from Jeffrey Cohen with Ladenburg Thalmann.

Hi. How are you?

Good. How are you?

Doing great. So just a couple of quick ones from me. So it looks like you had some good velocity coming out of the quarter. And your commentary for July is again that continues. So is there good confidence into August or at this point you're still kind of somewhat at the mercy of the hospitals as far as openings and access?

Yes, Jeff. That’s the volatility in the marketplace is regional. You never know when a territory is going to open up or have a flare-up. We’ve actually through Florida, Texas and California continue to see elective cases go on even as you see heightened cases there. So we’re really at the mercy of the elective procedures that you want to say. But yeah, at the end of the day, we continue to operate and execute this and we’re seeing good lift and patients want their surgeries. Even though sometimes they call them elective procedures, spine cases are not always elective, and surgeons are treating those patients when they need care.

Okay, I understand. I have one more quick question regarding the cash and debt situation. After Q2, if we adjust for the $50 million repayment from the approximate $123 million in cash, and account for the $50 million on the TED, plus the $13 million in Medicare that should be removed in the third quarter, is that correct?

Yeah. That’s the right way to look at it, Jeff, except it will peel off in Q3 and Q4, but by the end of the year, we expect it to be down to zero.

Okay. Perfect. That’s it for me. Looking forward to some of the NASS data. Thanks, again.

Thank you.

And your next question comes from Ryan Zimmerman with BTIG.

Hi. This is actually Max on for Ryan this morning. Just wanted to follow up on cash flow a little bit. I was impressed by the positive cash flow in the quarter and it seems like based on your decision to repay half of that $100 million revolving credit facility that if you’re feeling pretty good about your ability to generate some positive cash flow consistently moving forward. But just given the positive cash flow are looking at maybe accelerating some investments in R&D and being a bit more aggressive in terms of hiring new sales reps than you would have expected a few months ago.

Yeah. It’s a good question, Matt. Regarding the numbers, I’ll answer some of the questions and then turn it over to Jon in terms of outlook, but with regards to operating cash flow, we did count the CARES Act money, roughly $18 million, as income that positively impacted our operating cash flow. We expect to have a negative burn as I said a second ago, as we repay as Medicare recoups roughly $14 million of advanced payments that we got in April. So that will put negative pressure on our cash flow in Q3 and Q4. Overall, I’d say we continue to be cautiously optimistic and we’ll sort of take our foot off the break and invest in the areas where we feel like we need to grow and invest in our top line.

Yeah. Matt, we continue to be incredibly disciplined. As we told you in February, we’re transitioning the business, and we have key focus areas of investment; R&D being one of them, but we’ve not taken our foot off of that investment, where we need to come out of this market, this COVID activity and be poised to accelerate in the marketplace and we’re doing that. You’ll see that as far as with the Firebird SI, JuniOrtho and then as we come into NASS, you’ll see more results of that activity and we’re looking forward to that. But we continue to invest in a very disciplined way, and we think it’s a good time to be doing that as we work through this transition.

Got it. It’s really helpful. Thank you for that commentary. I have a couple of follow-up questions. You put together another strong quarter with the M6 desk, and I know you previously guided that it would be $15 million to $17 million in 2020 pre-COVID. From my calculations, it looks like you realized about $7 million in the first half of the year. I'm trying to gauge where you see this going in the latter half of the year. It seems like the $15 million to $17 million target is still achievable. Additionally, can you provide insight into the potential market for the product and how revenue from M6 might develop over the next couple of years? I realize it’s difficult to predict given the COVID situation, but any commentary would be appreciated.

So as you heard the commentary, we’re very bullish on the M6. And the challenge is just the dynamics of the marketplace and if we get slowed month and it takes off that FX long haul, but we are positive about where we’re going. We’ve seen that continue to grow through COVID, and we continue to invest. We trained as we talked about 75 additional surgeons and they brought in approximately $1 million in that quarter. And so we continue to execute on that. What the overall market is, there are different fault points out there, but it’s right now, it’s over a $200 million market, and we will get our portion of that share and that’s our focus to go out and get short share in this market space.

Got it. Thank you. And then, last one for me is, in regard to FITBONE. And just kind of going back to your first quarter earnings transcript and then more recently during some investor conferences in May and June. I think you’re more optimistic at those investor conferences in May and June following it on the primary growth drivers of over the next six months to 12 months, whereas on the first quarter earnings call. You made some comments around not expecting the product to materially contribute to extremities near term. I’m just trying to reconcile those two comments a little bit. Is there something specific that you saw that maybe made you think, where you think the near-term potential for FITBONE or has it always kind of been the case that you viewed it as a main growth driver over the next six months to 12 months?

Yes. FITBONE was an asset that we wanted in our portfolio, a product that basically we’ve not only got FITBONE but FITSPINE. And so it was a key strategic acquisition for us. We knew there were going to be activities to transition that business into the US, the product in the US for FITBONE. As we are making those transitions, I highlighted in my prepared remarks, we’re continuing to invest, we’re on track and we’re seeing traction, especially in Europe as far as that goes. But we were very modest in our projections for the first year of FITBONE as we do that transition, but the integration is on track.

Your next question comes from Jim Sidoti of Sidoti.

Good morning. Glad to hear you’re safe and found in Dallas. A couple of quick ones. For the M6 sales you reported that the US only number, correct?

M6, that’s correct.

The $3.6 million?

Correct. Yes. That’s right, Jim.

Okay. I just wanted to confirm that I heard you correctly. September usually sees a decline compared to the June quarter, but this year is quite different. Are you suggesting that September sales are likely to increase sequentially?

We think that Q3 based on what we’ve seen so far in July will trend above Q2, if trends hold.

Yes. Jim, the hard part about this year is that typically there are vacations and activities that go on in July and August. And we don’t see those when we’re talking to the physicians, the surgeons we’re talking to. So it’s a hard one to predict year-on-year direction that, but we see Q3 and Q4 being ahead of Q2.

Okay. And then the tax charge in the quarter, can you just tell me again what that was for and is that over now at this point that reconciliation process?

Right. Well, overall for the year, we’re going to have a GAAP tax benefit just based on the significance of the tax reserves that we were able to release as Fact Sheets expired. But with regards to the quarter itself, we saw the reversal of some of the items that we would anticipated from some of the congressional relief at the end of the first quarter was reversed with regards to the loss carrybacks and so we had to take a different position and catch the books up on a year-to-date basis for that change.

Okay. All right. And then Jon, you talked a little bit about classification for the stimulation products. Did you say, when you expected FDA decision to happen?

Well, the panel meeting is on September 8th. And typically the process there is that the panel will make a recommendation to the FDA and then they take it back and make that final decision. So we don’t know the exact timeframe. We know the panel will make a decision on September 8, but what the FDA does with that is unclear. It’s in their hands at that point in time.

And let’s say that the device does get down classified, how long do you think it would take new players to conduct studies and get products into the marketplace?

Yeah. In this particular panel, it’s different because oftentimes, people are asking for a reclassification. There is a company that comes in and wants it down classified. This is purely FDA administrative activity. There is no company out there actually asking for this. And the BGS coalition is asking for them to maintain Class III because of all the reasons we’ve highlighted. So we don’t know if there’s even anybody out there who would take advantage of it right now.

Okay. Yeah. Even if theoretically it was down classified, it sounds like it would be months if not years before any new players got into this space?

Yeah. Someone would have to run clinical trials, set up their contracts, set up their reimbursement and all. And so there is, even if the 510-K with special controls or special considerations, those typically now require clinical data. Everyone I’ve seen so far has required clinical data. So someone would have to come, petition the FDA and then run a clinical study and then basically present that to FDA. So it would be more like years in that regard than shorter period of time.

Okay. And for my last question, you have a significant business in Europe. Can you describe how you perceive the recovery there compared to the recovery in the US? Do you believe it is several months ahead of what we are seeing in the US?

Jim, you need to analyze it on a country-by-country basis. If you look at regions like the Scandinavian and Nordic countries, they are leading the way. Italy is performing well, and Germany is also doing well. However, the UK is lagging behind and is still progressing very slowly because it has been slower to feel the effects of COVID. Overall, while there are differences between countries, most are returning to business and adapting to a lifestyle influenced by COVID, and they are getting back to their daily routines.

All right. Thank you.

Thanks, Jim.

Thank you, Jim.

And I’m showing no further questions at this time. I would now like to turn the conference back to Jon Serbousek.

Thanks, operator. We appreciate everyone’s time and taking your time this morning. We look forward to updating you on our progress at our next quarterly call. Have a great day.

Ladies and gentlemen, this concludes today’s conference. Thank you for your participation and have a wonderful day. You may all disconnect.